These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34383746)

  • 1. A computational method for identifying an optimal combination of existing drugs to repair the action potentials of SQT1 ventricular myocytes.
    Jæger KH; Edwards AG; Giles WR; Tveito A
    PLoS Comput Biol; 2021 Aug; 17(8):e1009233. PubMed ID: 34383746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
    Jæger KH; Wall S; Tveito A
    PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.
    Odening KE; Bodi I; Franke G; Rieke R; Ryan de Medeiros A; Perez-Feliz S; Fürniss H; Mettke L; Michaelides K; Lang CN; Steinfurt J; Pantulu ND; Ziupa D; Menza M; Zehender M; Bugger H; Peyronnet R; Behrends JC; Doleschall Z; Zur Hausen A; Bode C; Jolivet G; Brunner M
    Eur Heart J; 2019 Mar; 40(10):842-853. PubMed ID: 30496390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.
    Lee HA; Hyun SA; Byun B; Chae JH; Kim KS
    PLoS One; 2018; 13(4):e0195577. PubMed ID: 29630634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.
    Luo C; Wang K; Zhang H
    PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
    Bodi I; Franke G; Pantulu ND; Wu K; Perez-Feliz S; Bode C; Zehender M; zur Hausen A; Brunner M; Odening KE
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1163-71. PubMed ID: 23718892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
    Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
    Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
    Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
    Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
    Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
    J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
    Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
    J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patch-Clamp Recording from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Improving Action Potential Characteristics through Dynamic Clamp.
    Verkerk AO; Veerman CC; Zegers JG; Mengarelli I; Bezzina CR; Wilders R
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28867785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Testing in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
    Zhao Z; Li X; El-Battrawy I; Lan H; Zhong R; Xu Q; Huang M; Liao Z; Lang S; Zimmermann WH; Cyganek L; Wieland T; Akin I; Zhou XB; Borggrefe M
    Clin Pharmacol Ther; 2019 Sep; 106(3):642-651. PubMed ID: 30947366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the heart's electrical properties by the anticonvulsant drug retigabine.
    Rubi L; Kovar M; Zebedin-Brandl E; Koenig X; Dominguez-Rodriguez M; Todt H; Kubista H; Boehm S; Hilber K
    Toxicol Appl Pharmacol; 2017 Aug; 329():309-317. PubMed ID: 28641963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias.
    Brandão KO; van den Brink L; Miller DC; Grandela C; van Meer BJ; Mol MPH; de Korte T; Tertoolen LGJ; Mummery CL; Sala L; Verkerk AO; Davis RP
    Stem Cell Reports; 2020 Nov; 15(5):1127-1139. PubMed ID: 33176122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
    Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
    Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-Scale Simulation of the Phenotypical Variability Induced by Loss-of-Function Long QT Mutations in Human Induced Pluripotent Stem Cell Cardiomyocytes.
    Paci M; Casini S; Bellin M; Hyttinen J; Severi S
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.
    Shinozawa T; Nakamura K; Shoji M; Morita M; Kimura M; Furukawa H; Ueda H; Shiramoto M; Matsuguma K; Kaji Y; Ikushima I; Yono M; Liou SY; Nagai H; Nakanishi A; Yamamoto K; Izumo S
    Stem Cell Reports; 2017 Feb; 8(2):226-234. PubMed ID: 28111276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
    De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.